CEA (Carcinoembryonic Antigen)

Pick Ordered or Not ordered to see the note.

Indicated when

• —Scheduled surveillance for recurrence in a patient previously treated for colorectal cancer, typically every 3 to 6 months for 5 years as part of a structured follow-up plan, alongside history, exam, and imaging/colonoscopy on their own schedules [1]
• —Monitoring a known CEA-producing malignancy under the direction of the treating oncology or surgical team, in accordance with Cancer Care Ontario guidelines for following an established malignancy [2]

Not indicated when

• —Screening for colorectal or other cancer in a patient with no personal history of a CEA-producing malignancy
• —Investigating vague or non-specific symptoms (e.g., fatigue, weight change) with no diagnosed malignancy and no other specific indication
• —As part of a general 'wellness' or tumour-marker panel

Why not

CEA is not specific to one cancer type and is not a validated screening test. The Choosing Wisely oncology position is that tests to detect recurrent cancer in asymptomatic patients should only be ordered where there is a realistic expectation that earlier detection improves survival [3]; this is why CEA's established, OHIP-recognized role is a structured, guideline-timed surveillance schedule after a diagnosed and treated malignancy (every 3 to 6 months for 5 years, per [1]), rather than an isolated or 'just in case' check outside that schedule or outside a cancer diagnosis.

Better first step

For a patient with no diagnosed malignancy, investigate presenting symptoms directly: colorectal symptoms (rectal bleeding, persistent change in bowel habit, unexplained weight loss, iron deficiency) warrant assessment and colonoscopy through standard pathways, not a CEA level. For a patient previously treated for colorectal cancer, follow the structured surveillance schedule (history, exam, and CEA every 3 to 6 months for 5 years, plus imaging and colonoscopy as scheduled) rather than ordering an unscheduled one-off test [1].

Typical ND rationale

An ND may include CEA in a general tumour-marker or cancer-screening panel, reasoning that a normal result is reassuring and an elevated one would prompt earlier investigation, particularly for a patient with gastrointestinal symptoms or a family history of colorectal cancer.

Ontario coverage & CONO orderability

OHIP status

insured_conditional

CEA is insured only when carried out in accordance with Cancer Care Ontario guidelines for following established malignancies [2]; a family physician ordering CEA outside that context, for example as a screening or 'just in case' test in a patient with no cancer diagnosis, is not an insured indication. ND-ordered testing is patient-paid regardless [4, 5].

CONO orderable

Yes — CONO list #37

CONO list item 37, blood: 'Carcinoembryonic Antigen.'

Linked conditions

• Tumour markers to check for 'hidden' cancer ↗

Counselling script

“CEA is a follow-up test for people already diagnosed with and treated for certain cancers, mainly colorectal cancer, checked on a set schedule alongside scans and colonoscopy. Since that history doesn't apply here, a CEA level wouldn't tell us much and could raise a false alarm, since it can be elevated by things other than cancer. If you're specifically worried about colorectal cancer, let's talk about your symptoms and whether colonoscopy or stool testing makes sense.”

Revisit if

• —A diagnosis of colorectal cancer or another CEA-producing malignancy is made
• —Colorectal symptoms develop (rectal bleeding, persistent change in bowel habit, unexplained weight loss, iron deficiency anemia)

References

1. [1]Cancer Care Ontario, endorsed by American Society of Clinical Oncology (2013). Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: ASCO clinical practice guideline endorsement of the Cancer Care Ontario guideline. linkolder guidelineCEA testing every 3 to 6 months for 5 years is part of structured colorectal cancer follow-up
2. [2]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkOHIP insures CEA only in accordance with Cancer Care Ontario guidelines for following established malignancies
3. [3]Canadian medical oncology societies / Choosing Wisely Canada (2025). Oncology recommendations. linkDon't order recurrence-detection tests in asymptomatic patients without a realistic expectation that early detection improves survival
4. [4]Government of Ontario (e-Laws) (2026). Health Insurance Act, R.R.O. 1990, Reg. 552: General, s. 22 (insured laboratory services). linkA lab test is insured only when ordered by a physician, midwife, or NP who has clinically assessed the patient
5. [5]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkTests ordered by anyone other than an authorized provider, including NDs, are not insured services